Morphosys Ag News Today

More than 30 years after entering the scene as a first-generation monoclonal antibody pioneer, Morphosys AG is to be acquired by Novartis AG for €2.7 billion (US$2.9 billion). The all-cash deal, announced after Nasdaq closed on Feb. 5, will see Novartis paying €68 per share, a premium of 94% to the average daily price in the month leading up to Jan. 25, when rumors of a takeover started swirling.

European stocks finished lower Tuesday, with the Stoxx Europe 600 index falling 0.30% to 457.04. The French CAC 40 index fell 0.21% to 7,250.13, the FTSE 100...

European stocks increased Wednesday, as the Stoxx Europe 600 index finished up 0.30% to 457.24. The French CAC 40 index increased 0.43% to 7,260.73, the...

European stocks finished flat Tuesday, with the Stoxx Europe 600 index closing at 455.85. The French CAC 40 index fell 0.24% to 7,229.45, the FTSE 100 index...

Key Insights Significantly high institutional ownership implies MorphoSys' stock price is sensitive to their trading...

Morgan Stanley is bullish on pelabresib, currently awaiting results from its Phase 3 MANIFEST-2 trial.

Unveiling the hidden risks behind the seemingly attractive valuation of MorphoSys AG (MOR)

Investegate announcements from MorphoSys AG, Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Investegate announcements from MorphoSys AG, Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Investegate announcements from MorphoSys AG, Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution